Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
Follow-Up Questions
Who is the CEO of Nuvectis Pharma Inc?
Mr. Ron Bentsur is the Chairman of the Board of Nuvectis Pharma Inc, joining the firm since 2020.
What is the price performance of NVCT stock?
The current price of NVCT is $6.48, it has increased 1.25% in the last trading day.
What are the primary business themes or industries for Nuvectis Pharma Inc?
Nuvectis Pharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Nuvectis Pharma Inc market cap?
Nuvectis Pharma Inc's current market cap is $164.9M
Is Nuvectis Pharma Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Nuvectis Pharma Inc, including 3 strong buy, 8 buy, 1 hold, 0 sell, and 3 strong sell
